PTO
IAP82
MAR 17 2006
PATENT & TRADEMARK OFFICE

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/680,160; Confirmation 5791
Filing Date	10/8/2003
First Named Inventor	Goldenberg
Art Unit	1644
Examiner Name	Phuong N. Huynh
Attorney Docket Number	329197

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
PNH	1	EP 0 336 631 B1	7-7-1993	Goldenberg		X
	2	DE 689 07 430 T2	10-11-1989	Goldenberg		
	3	89303080.9	3-29-1989	Goldenberg		X
	4	EP 0 256 714 A2	2-24-1988	Stevens		X
	5	EP 0 217 404 A2	4-8-1987	Tamura		X
	6	EP 0 118 915	9-19-1984	Yamamura		X

Examiner Signature	PNH	Date Considered	4/3/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B(07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete If Known	
Application Number	10/680,160; Confirmation 5791
Filing Date	10-8-2003
First Named Inventor	Goldenberg
Art Unit	1644
Examiner Name	Phuong N. Huynh
Attorney Docket Number	329197

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	7	Bird & Bird, Solilcitors for the Defendant, F. Hoffmann-LaRoche LTd. v. Immunomedics, Inc., In the High Court of Justice Chancery Division Patents Court, STATEMENT OF REASONS, HC-04-C-02335, 10-21-2004	x
	8	Vossius & Partner, Official document from F. Hoffmann-La Roche AG/Immunomedics, Inc., May 19, 2004	
	9	~~Vossius & Partner, DE Patent 336 631, December 7, 2004, Letter from Dr. Jurgen Meier~~	
	10	Vossius & Partner, Letter from Dr. Hans-Rainer Jaaenichen, re: F. Hoffmann-La Roche AG/Immunomedics, Inc., December 10, 2004	
	11	Bohmann & Loosen, EP Application 04776666.2, dated March 14, 2006, replacement page 5	x
	12	Hoffmann-Eitle, Translation of the Brief as submitted ot he Federal Patent Court by Vossius & Partner, dated Decembe 7, 2004	x
	13	~~Hoffmann-Eitle, "Cytotoxic Therapy" Immunomedics, Hoffmann-La Roche AG, Basel, CH Immunomedics, Inc., January 20, 2005,~~	
	14	Hoffmann-Eitle, Translation of the Response to the Federal Patents Court, January 20, 2005,	x
	15	Motoyoshi, et al., "Clinical Application of Partially Purified Human Urinary Colony-Stimulating Factor," Immunobiol., vol. 172, pp. 205-212 (1986)	x
	16	Bronchud, M.H., et al., "Phase I/II study of recombinant human granulocyte colony-stimulating factor in Patients receiving intensive chemotherapy for small cell lung cancer" Br.J.Cancer (1987), 56, pgs. 809-813, The Macmillian Press Ltd., 1987	x
	17	Morstyn, G., et al., "Effect of Granulocyte Colony Stimulating Factor on Neutropenia Induced by Cytotoxic Chemotherapy," The Lancet, March 26, 1988, pgs. 667-672	x

Examiner Signature		Date Considered	4/3/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B(07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete If Known	
Application Number	10/680,160; Confirmation 5791
Filing Date	10-8-2003
First Named Inventor	Goldenberg
Art Unit	1644
Examiner Name	Phuong N. Huynh
Attorney Docket Number	329197

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	18	MOORE, A. S. Malcolm, et al., "Synergy of Interleukin 1 and Granulocyte Colony-Stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5 fluorouracil treatment of mice," Proc. Natl. Acad. Sci., USA Vol. 84, pp. 7134-7138, October 1987 Cell Biology	x
	19	Welte, Karl, et al., "Recombinant Human Granulocyte Colony-Stimulating Factor," J. Exp. Med. The Rockefeller University Press 0022-1007/87/04/0941/08, Volme 165 April 1987 pgs 941-948	x
	20	Gillio, A. P., et al., "Effects of Recombinant Human Granulocyte-Colony Stimulating Factor on Hematopoietic Reconstitution After Autologous Bone Marrow Transplantation in Primates" Transplantation Proceedings, Vol XIX, No. 6, Suppl 7 (December 1987, pp 153-156	x
	21	Mochizuki, Diane Y., "Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1" Proc. Natl. Acad. Sci. USA Vol. 84, pp. 5267-5271, August 1987 Cell Biology	x
	22	Washburn, L. C., et al., "90Y-Labeled Monoclo9nal Antibodies for Cancer Therapy" Nucl. Med. Biol. Vol. 13, No. 4, pp. 453-456, 1986 Int. J. Radiat. Appl. Instrum. Part B 0883-2897/86	x
	23	Donahue, Robert E., et al., "Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF" Nature Vol. 321 June 26, 1986	X
	24	Griffin, James D., MD, "Clinical Application of Colony-Stimulating Factors" Oncology January 1988, pgs. 15-23, Volume 2, Number 1	x
	25	Revkin, Andrew C., "Firm May Have Found Key to Treating Anemia" Los Angeles Times, January 22, 1987, Long Beach, Part 9, page 7,	x
	26	Eschbach, Joseph W., et al., "Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin" The New England Journal of Medicine, Vol. 316, No. 2, pgs 73-78 January 8, 1987	x
	27	Wood, P., et al., "Cisplatin-Induced Anemia is Correctable with Erythropoietin" Anemias, 119 ,	x
	28	Oster, Wolfgang, et al., "Ereythropoietin prevents chemotherapy-induced anemia: Case Report" original article, Blut (1990) 60: 88-92 Springer-Verlag 1990	x

Examiner Signature		Date Considered	4/3/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B(07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/680,160; Confirmation 5791
Filing Date	10/8/2003
First Named Inventor	Goldenberg
Art Unit	1644
Examiner Name	Phuong N. Huynh
Attorney Docket Number	329197

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PNH	29	Miller, Carole B., et al., "Decreased Erythropoietin Response in Patients with the Anemia of Cancer" The New England Journal of Medicine, Volume 322, No. 24, June 14, 1990 Massachusetts Medical Society	x
	30	Editorial, "Recombinant Erythropoietin Therapy in Cancer Patients" Journal of Clinical Oncology, Vol. 8, No. 6, June 1990, pgs. 949951	x
	31	Ewing, James "The Clinical Use of Colony Stimulating Factors" 0732-0582/91/0410-0159 Annu. Rev. Immunol. 1991, pgs. 159-191	x
	32	Platanias, Leonidas C., "Treatment of Chemotherapy-Induced Anemia With Recombinant Human Erythropoietin in Cancer Patients" Journal of Clinical Oncology, Vol. 9, No. 11 (November) 1991, pp 2021-2026	x
	33	Smith, David H., "Serum Immunoerythropoietin Levels in Patients with Cancer Receiving Cisplatin-Based Chemotherapy" Cancer September 1, 1991, Vol. 68, pgs 1101-1105	x
↓	34	Graber, Stanley E., "Erythropoietin: Biology and Clinical Use" Hematopoietic Growth Factors 0889-8588/89 Hematology/Oncology, Clinics of North america, Vol. 3, No. 3, September 1989	

Examiner Signature		Date Considered	4/3/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.